NCT01222299

Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 89 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine the safety and efficacy of bepotastine besilate nasal product in seasonal allergic rhinitis patients.

Conditions

• Seasonal Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	bepotastine besilate nasal product - low dose	sterile nasal product
DRUG	bepotastine besilate nasal product - medium dose	sterile nasal product
DRUG	bepotastine besilate nasal product - high dose	sterile nasal product
DRUG	placebo comparator nasal product	sterile nasal product

Timeline

• Start date: 2010-05-01
• Primary completion: 2010-08-01
• Completion: 2010-08-01
• First posted: 2010-10-18
• Last updated: 2020-10-05
• Results posted: 2020-09-14

Locations

1 site across 1 country: United States